Mirati Therapeutics (Nasdaq:MRTX) - Aktienkurs, Nachrichten und Analyse

MRTX Aktienübersicht

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States.

Über das Unternehmen

MRTX grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	3/6
Künftiges Wachstum	2/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	5/6
Dividenden	0/6

Belohnungen

85.7% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes jährliches Umsatzwachstum 42.24%

Risikoanalyse

Die Aktionäre wurden im vergangenen Jahr verwässert

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert

Signifikante Insiderverkäufe in den letzten 3 Monaten

Mirati Therapeutics, Inc. Wettbewerber

Avidity Biosciences

NasdaqGM:RNA

US$4.1b

Ultragenyx Pharmaceutical

NasdaqGS:RARE

US$3.6b

Alkermes

NasdaqGS:ALKS

US$4.2b

Immunovant

NasdaqGS:IMVT

US$4.0b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Mirati Therapeutics
Historische Aktienkurse
Aktueller Aktienkurs	US$58.70
52-Wochen-Hoch	US$64.41
52-Wochen-Tief	US$27.30
Beta	0.77
11 Monat Veränderung	-0.41%
3 Monate Veränderung	6.32%
1 Jahr Veränderung	18.92%
33 Jahre Veränderung	-71.20%
5 Jahre Veränderung	-5.55%
Veränderung seit IPO	590.59%

Aktuelle Nachrichten und Updates

Recent updates

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Oct 05

Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?

Jun 22

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

May 17

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Feb 01

Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates

Dec 09

We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Oct 08

Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

Sep 11

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Aug 08

Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years

Jun 21

Aktionärsrenditen

	MRTX	US Biotechs	US Markt
7D	-0.5%	2.1%	-0.5%
1Y	18.9%	12.0%	24.2%

Rendite im Vergleich zur Industrie: MRTX übertraf die Branche US Biotechs, die im vergangenen Jahr eine Rendite von 7.4 erzielte.

Rendite vs. Markt: MRTX entspricht dem US Markt, der im vergangenen Jahr eine Rendite von 25.6 erzielte.

Preisvolatilität

Is MRTX's price volatile compared to industry and market?
MRTX volatility
MRTX Average Weekly Movement	1.0%
Biotechs Industry Average Movement	10.4%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

Stabiler Aktienkurs: MRTX hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: MRTXDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 10% auf 1% zurückgegangen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1995	587	Chuck Baum	www.mirati.com

Mirati Therapeutics, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Mirati Therapeutics im Vergleich zum Marktanteil des Unternehmens?
MRTX grundlegende Statistiken
Marktanteil	US$4.12b
Gewinn(TTM)	-US$725.88m
Umsatz(TTM)	US$38.19m

107.8x

Kurs-Umsatz-Verhältnis

-5.7x

Kurs-Gewinn-Verhältnis

Ist MRTX zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
MRTX Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$38.19m
Kosten der Einnahmen	US$510.48m
Bruttogewinn	-US$472.29m
Sonstige Ausgaben	US$253.59m
Umsatz	-US$725.88m

Zuletzt gemeldete Gewinne

Sep 30, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-10.35
Bruttomarge	-1,236.66%
Nettogewinnspanne	-1,900.65%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich MRTX auf lange Sicht entwickelt?

Historische Performance und Vergleiche

MRTX Aktienübersicht

Belohnungen

Risikoanalyse

Mirati Therapeutics, Inc. Wettbewerber

NasdaqGM:RNA

US$4.1b

NasdaqGS:RARE

US$3.6b

NasdaqGS:ALKS

US$4.2b

NasdaqGS:IMVT

US$4.0b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Recent updates

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Price target increased by 9.7% to US$60.00

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

New major risk - Share price stability

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Mirati Therapeutics, Inc. Announces CFO Changes Effective as of September 8, 2023

Insufficient new directors

Mirati Therapeutics, Inc. Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers Through Novel Approach to MTA-Cooperative PRMT5 Inhibition

Second quarter 2023 earnings: EPS exceeds analyst expectations

Mirati Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of Krazati (Adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with A Krasg12c Mutation

Price target decreased by 8.0% to US$60.64

New minor risk - Insider selling

Mirati Therapeutics Appoints Carol Gallagher, Pharm.D. as New Independent Director

Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?

Chief Financial Officer recently sold US$172k worth of stock

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO(R)

Insufficient new directors

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Consensus revenue estimates increase by 23%

Consensus revenue estimates decrease by 28%

Mirati Therapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

CEO & Director recently sold US$135k worth of stock

Mirati Therapeutics, Inc. Announces U.S. Food and Drug Administration Clears the Investigational New Drug (Ind) Application of MRTX1133

Founder recently sold US$170k worth of stock

Executive VP & Chief Scientific Officer recently sold US$104k worth of stock

Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer

Mirati Therapeutics, Inc. Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates

Price target decreased to US$91.40

Executive VP & Chief Scientific Officer recently sold US$156k worth of stock

Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Mirati Therapeutics, Inc. Announces Update for the Phase 3 SAPPHIRE Study

Founder exercised options and sold US$5.7m worth of stock

Mirati Therapeutics Reportedly Seen as Takeover Target Once Again

Consensus revenue estimates increase by 48%

Mirati Therapeutics, Inc. Announces Management Changes

Mirati Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

Mirati: A Potential Blockbuster Stock, Will Need Patience

Mirati Therapeutics, Inc. Presents Late-Breaking Adagrasib Monotherapy and Combination

Mirati jumps 11% as Amgen meets key goal for rival cancer drug

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 15%

Mirati gains as Amgen posts new combination data for rival cancer drug

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Mirati Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years

Mirati Therapeutics, Inc. Announces Results of A Prospective Analysis from the Phase 1B Cohort of the KRYSTAL-1

Aktionärsrenditen

Erträge & Einnahmen